Published in Sci Transl Med on November 25, 2015
T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs (Treg) | NCT01210664
T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT) | NCT02772679
Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell Therapy. Can J Gastroenterol Hepatol (2016) 1.39
Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival. J Am Soc Nephrol (2017) 1.38
IL233, A Novel IL-2 and IL-33 Hybrid Cytokine, Ameliorates Renal injury. J Am Soc Nephrol (2017) 1.38
Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest (2016) 0.99
A pilot study showing associations between frequency of CD4(+) memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes. Clin Immunol (2016) 0.92
The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements. Immunity (2016) 0.91
Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood (2016) 0.84
Inducing and Administering Tregs to Treat Human Disease. Front Immunol (2016) 0.84
Generation of stem cell-derived β-cells from patients with type 1 diabetes. Nat Commun (2016) 0.82
Life and death of β cells in Type 1 diabetes: A comprehensive review. J Autoimmun (2016) 0.81
Increasing Regulatory T Cells With Interleukin-2 and Interleukin-2 Antibody Complexes Attenuates Lung Inflammation and Heart Failure Progression. Hypertension (2016) 0.81
Increased DNA methylation variability in type 1 diabetes across three immune effector cell types. Nat Commun (2016) 0.80
Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood (2016) 0.78
Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis. Hepatology (2016) 0.78
Regulatory T Cell Therapy for Ischemic Stroke: how far from Clinical Translation? Transl Stroke Res (2016) 0.78
miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. Blood (2016) 0.78
Regulatory T Cell Immunotherapy for Type 1 Diabetes: A Step Closer to Success? Cell Metab (2016) 0.78
Hepatic stellate cells increase the immunosuppressive function of natural Foxp3+ regulatory T cells via IDO-induced AhR activation. J Leukoc Biol (2016) 0.76
Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them? J Immunol (2016) 0.76
Immunometabolism and autoimmunity. Immunol Cell Biol (2016) 0.76
Immunotherapy for type 1 diabetes. J Endocrinol Invest (2017) 0.76
The regulation of immune tolerance by FOXP3. Nat Rev Immunol (2017) 0.76
One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance. JCI Insight (2016) 0.75
Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives. Front Immunol (2016) 0.75
Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes. J Transl Med (2016) 0.75
Advances in islet encapsulation technologies. Nat Rev Drug Discov (2016) 0.75
Development of Auto Antigen-specific Regulatory T Cells for Diabetes Immunotherapy. Immune Netw (2016) 0.75
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annu Rev Pathol (2016) 0.75
ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight (2017) 0.75
Economic 3D-printing approach for transplantation of human stem cell-derived β-like cells. Biofabrication (2016) 0.75
Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. Mol Ther Methods Clin Dev (2016) 0.75
Nutrients and the Pancreas: An Epigenetic Perspective. Nutrients (2017) 0.75
FVIII-specific human chimeric antigen receptor (CAR) T-regulatory cells suppress T-and B-cell responses to FVIII. Blood (2016) 0.75
Regulatory T Cells: Central Concepts from Ontogeny to Therapy. Transfus Med Rev (2016) 0.75
Growth Arrest-Specific 6 Enhances the Suppressive Function of CD4(+)CD25(+) Regulatory T Cells Mainly through Axl Receptor. Mediators Inflamm (2017) 0.75
Progress and challenges for treating Type 1 diabetes. J Autoimmun (2016) 0.75
Utilization of leukapheresis and CD4 positive selection in Treg isolation and the ex-vivo expansion for a clinical application in transplantation and autoimmune disorders. Oncotarget (2016) 0.75
T cell receptor repertoires after adoptive transfer of expanded allogeneic regulatory T cells. Clin Exp Immunol (2016) 0.75
Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes. Front Immunol (2017) 0.75
A Deeper Look into Type 1 Diabetes - Imaging Immune Responses during Onset of Disease. Front Immunol (2016) 0.75
A Novel mTORC1-Dependent, Akt-Independent Pathway Differentiates the Gut Tropism of Regulatory and Conventional CD4 T Cells. J Immunol (2016) 0.75
Tumor Progression Locus 2 (Tpl2) Activates the Mammalian Target of Rapamycin (mTOR) Pathway, Inhibits Forkhead Box P3 (FoxP3) Expression, and Limits Regulatory T Cell (Treg) Immunosuppressive Functions. J Biol Chem (2016) 0.75
MC5r and A2Ar Deficiencies During Experimental Autoimmune Uveitis Identifies Distinct T cell Polarization Programs and a Biphasic Regulatory Response. Sci Rep (2016) 0.75
Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7Rα antibodies in NOD mice. BMC Immunol (2017) 0.75
Spatiotemporal Dynamics of Insulitis in Human Type 1 Diabetes. Front Physiol (2016) 0.75
B cell-targeted immunotherapy for type 1 diabetes: What can make it work? Discov Med (2016) 0.75
Antigen-specific immunotherapies in rheumatic diseases. Nat Rev Rheumatol (2017) 0.75
Awards in Transplantation Science Recognize the Best Manuscripts Published in Transplantation. Transplantation (2016) 0.75
Molecular mechanisms underlying Th1-like Treg generation and function. Cell Mol Life Sci (2017) 0.75
Regulatory T cells: Tolerance Induction in Solid Organ Transplantation. Clin Exp Immunol (2017) 0.75
Foxp3(+) Tregs are recruited to the retina to repair pathological angiogenesis. Nat Commun (2017) 0.75
Tolerogenic Nanoparticles to Treat Islet Autoimmunity. Curr Diab Rep (2017) 0.75
IL-2-Mediated In Vivo Expansion of Regulatory T Cells Combined with CD154-CD40 Co-Stimulation Blockade but Not CTLA-4 Ig Prolongs Allograft Survival in Naive and Sensitized Mice. Front Immunol (2017) 0.75
Single and combined effect of retinoic acid and rapamycin modulate the generation, activity and homing potential of induced human regulatory T cells. PLoS One (2017) 0.75
Mild hypothermia provides Treg stability. Sci Rep (2017) 0.75
Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision. Front Immunol (2017) 0.75
PKC-ѳ is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cells. Sci Rep (2017) 0.75
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature (2010) 5.16
Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA (2007) 4.29
Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol (2012) 3.81
DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol (2007) 3.80
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S A (2003) 2.94
Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care (2015) 2.79
Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest (2006) 2.58
Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52
Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol (2013) 2.23
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes (2009) 1.88
Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood (2004) 1.77
Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J Exp Med (1990) 1.35
CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology (2013) 1.30
Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med (2013) 1.29
Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med (2015) 1.23
Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest (2014) 1.22
Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion. J Immunol (2006) 1.06
Dominant Th2 differentiation of human regulatory T cells upon loss of FOXP3 expression. J Immunol (2011) 0.97
Harnessing FOXP3+ regulatory T cells for transplantation tolerance. J Clin Invest (2014) 0.95
T cells in the control of organ-specific autoimmunity. J Clin Invest (2015) 0.93
CCL-21 conditioned regulatory T cells induce allotolerance through enhanced homing to lymphoid tissue. J Immunol (2013) 0.90
The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opin Ther Targets (2015) 0.88